Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7VUX

Complex structure of PD1 and 609A-Fab

7VUX の概要
エントリーDOI10.2210/pdb7vux/pdb
分子名称Programmed cell death protein 1, Heavy chain of Fab fragment, Light chain of Fab fragment, ... (10 entities in total)
機能のキーワードpd1 fab complex, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数3
化学式量合計63178.27
構造登録者
Huang, H.,Zhu, Z.,Zhao, J.,Jiang, L.,Yang, H.,Deng, L.,Meng, X.,Ding, J.,Yang, S.,Zhao, L.,Xu, W.,Wang, X. (登録日: 2021-11-04, 公開日: 2021-11-17, 最終更新日: 2024-10-16)
主引用文献Zhao, J.,Jiang, L.,Yang, H.,Deng, L.,Meng, X.,Ding, J.,Yang, S.,Zhao, L.,Xu, W.,Wang, X.,Zhu, Z.,Huang, H.
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties.
Mabs, 14:2044435-2044435, 2022
Cited by
PubMed Abstract: Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20-30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune checkpoint target may have greater potential to enhance immune checkpoint blockade therapy. In this study, we identified an anti-PD1 monoclonal antibody, 609A, whose heavy chain can pair with a variety of light chains from different antibodies while maintaining its PD1 binding/blocking activity. Taking advantage of this property and using a linear F(ab') format, we successfully produced a series of tetravalent IgG-like BsAbs that simultaneously target PD1 and other immune checkpoint targets, including PDL1 and CTLA4. The BsAbs exhibited superior bioactivities in vitro and in vivo compared to their respective parental mAbs. Importantly, the BsAbs demonstrated the desired IgG-like physicochemical properties in terms of high-level expression, ease of purification to homogeneity, good stability and in vivo pharmacokinetics. In summary, we describe a novel and flexible plug-and-play platform to engineer IgG-like BsAbs with excellent development potential for clinical applications.
PubMed: 35239451
DOI: 10.1080/19420862.2022.2044435
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.64 Å)
構造検証レポート
Validation report summary of 7vux
検証レポート(詳細版)ダウンロードをダウンロード

227111

件を2024-11-06に公開中

PDB statisticsPDBj update infoContact PDBjnumon